Matches in Nanopublications for { ?s ?p "DDI between Selegiline and Thiotepa - Thiotepa, a strong CYP2B6 inhibitor, may decrease the metabolism and clearance of Selegiline, a CYP2B6 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Selegiline if Thiotepa is initiated, discontinued or dose changed."@en ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- drugbank_resource:DB01037_DB04572 title "DDI between Selegiline and Thiotepa - Thiotepa, a strong CYP2B6 inhibitor, may decrease the metabolism and clearance of Selegiline, a CYP2B6 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Selegiline if Thiotepa is initiated, discontinued or dose changed." assertion.